Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Janssen/Genmab Win 1st Anti-CD38 In Multiple Myeloma

This article was originally published in Scrip

Executive Summary

Johnson & Johnson Inc.'s subsidiary Janssen Biotech Inc. and its partner Genmab AS were the latest beneficiaries of the FDA's swift acting Office of Hematology and Oncology Products, which approved the firms' multiple myeloma drug Darzalex (daratumumab) well ahead of its March 9, 2016 expected goal date and just two months after the FDA accepted the medicines biologics license application (BLA).


Related Content

Expanded US Approval Set To Take Janssen’s Darzalex Higher
J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches
VC Roundup: Cleave Raises $37m To Maintain Phase I Momentum, Plus $233.5m In Recent Financings
Janssen Oncology Strategy: Take A Holistic Approach To R&D
Ten Programs To Watch Out For At ASCO


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst